The SCF(FBXO11) - XAB2 axis mediates DNA repair and therapeutic resistance in small cell lung cancer

SCF(FBXO11) - XAB2 轴介导小细胞肺癌的 DNA 修复和治疗耐药

• 批准号: 409474
• 负责人: Lok Benjamin
• 金额: $ 71.72万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2024-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409474&lang=en
• 关键词: Cisplatin; Crispr Genetic Screen; Dna Repair; Homologous Recombination; Lung Cancer; Parp Inhibitor; Patient-Derived Xenografts; Small Cell Lung Cancer; Treatment Resistance; Ubiquitin-Proteasome Pathway

In Canada, lung cancer is responsible for more deaths than colon, breast, and prostate cancer combined. Small cell lung cancer (SCLC) is a particularly aggressive subtype that represents approximately 15% of all lung cancers. Despite an initial response o

在加拿大，肺癌导致的死亡人数比结肠癌、乳腺癌和前列腺癌加起来还要多。小细胞肺癌（SCLC）是一种特别具有侵袭性的亚型，约占所有肺癌的15%。尽管最初的反应是